The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced

Boe Sandahl Sørensen, Niels Tørring, Mustafa Vakur Bor, Ebba Nexø

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Increased activity of the EGF system exerts a cell survival function in the presence of cytotoxic agents. The aim of our investigation was to identify the ligands and receptors from the EGF system, that are induced by the chemotherapeutic DNA damaging agent VP16 in bladder cancer cell lines. By use of real-time RT-PCR assays for all four receptors and six ligands from the EGF system we demonstrate that in HCV29 bladder cancer cells, amphiregulin, HB-EGF, and epiregulin mRNA levels are elevated (more than 100, 5, and 4 fold, respectively) by VP16. The remaining ligands (EGF, TGFalpha and betacellulin) are uninduced. The same was found for T24A bladder cancer cells, except that TGFalpha also was induced. The four receptors were reduced by VP16 in both cell lines. This demonstrates that the induction of the EGF system is mediated by an increased expression of a subset of the ligands, whereas the four receptors are reduced. For amphiregulin and HER1 we investigated with ELISA assays if the effects of VP16 also were observed at the protein level. We found that VP16 increase the amount of amphiregulin peptide both in the cell membrane and the culture medium. Similarly, the reduced EGF receptor mRNA expression correlated with reduced HER1 protein. Several investigations have shown that labile protein factors can be involved in the regulation of stress inducible growth factors and cytokines. We investigated if a labile protein regulates the expression of the subset of ligands that were induced with VP16. Blocking of protein neosynthesis with cycloheximide resulted in induced mRNA expression of exactly the same subset of ligands as observed with VP16 treatment of both HCV29 and T24A cells. This suggests that a labile protein factor regulates either the transcription or degradation of these mRNA's, and it can be speculated that VP16 also operate by inhibiting the activity of this factor. This is further stressed by the observation that combined treatment with cycloheximide and VP16 show no additive effect. In conclusion, we show that a subset of ligands from the EGF system is upregulated by VP16, whereas none of the four receptors are induced. This might represent a physiological response aimed at rescuing the cells.

OriginalsprogEngelsk
TidsskriftMolecular and Cellular Biochemistry
Vol/bind260
Udgave nummer1-2
Sider (fra-til)129-35
Antal sider7
ISSN0300-8177
StatusUdgivet - maj 2004

Fingeraftryk

Epidermal Growth Factor
Cells
Ligands
DNA
Messenger RNA
Transforming Growth Factor alpha
Proteins
Cycloheximide
Assays
Cell Line
Cytotoxins
Transcription
Cell membranes
Epidermal Growth Factor Receptor
Culture Media
ErbB Receptors
Real-Time Polymerase Chain Reaction
Cell Survival
Intercellular Signaling Peptides and Proteins
Cell Membrane

Citer dette

@article{6a7de7bc1bd745e7b19575d4eb357cae,
title = "The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced",
abstract = "Increased activity of the EGF system exerts a cell survival function in the presence of cytotoxic agents. The aim of our investigation was to identify the ligands and receptors from the EGF system, that are induced by the chemotherapeutic DNA damaging agent VP16 in bladder cancer cell lines. By use of real-time RT-PCR assays for all four receptors and six ligands from the EGF system we demonstrate that in HCV29 bladder cancer cells, amphiregulin, HB-EGF, and epiregulin mRNA levels are elevated (more than 100, 5, and 4 fold, respectively) by VP16. The remaining ligands (EGF, TGFalpha and betacellulin) are uninduced. The same was found for T24A bladder cancer cells, except that TGFalpha also was induced. The four receptors were reduced by VP16 in both cell lines. This demonstrates that the induction of the EGF system is mediated by an increased expression of a subset of the ligands, whereas the four receptors are reduced. For amphiregulin and HER1 we investigated with ELISA assays if the effects of VP16 also were observed at the protein level. We found that VP16 increase the amount of amphiregulin peptide both in the cell membrane and the culture medium. Similarly, the reduced EGF receptor mRNA expression correlated with reduced HER1 protein. Several investigations have shown that labile protein factors can be involved in the regulation of stress inducible growth factors and cytokines. We investigated if a labile protein regulates the expression of the subset of ligands that were induced with VP16. Blocking of protein neosynthesis with cycloheximide resulted in induced mRNA expression of exactly the same subset of ligands as observed with VP16 treatment of both HCV29 and T24A cells. This suggests that a labile protein factor regulates either the transcription or degradation of these mRNA's, and it can be speculated that VP16 also operate by inhibiting the activity of this factor. This is further stressed by the observation that combined treatment with cycloheximide and VP16 show no additive effect. In conclusion, we show that a subset of ligands from the EGF system is upregulated by VP16, whereas none of the four receptors are induced. This might represent a physiological response aimed at rescuing the cells.",
keywords = "Amphiregulin, Antineoplastic Agents, Phytogenic, Betacellulin, Cell Line, Tumor, Cell Membrane, Cycloheximide, Dose-Response Relationship, Drug, EGF Family of Proteins, Epidermal Growth Factor, Epiregulin, Etoposide, Gene Expression Regulation, Neoplastic, Glycoproteins, Humans, Intercellular Signaling Peptides and Proteins, Ligands, Protein Synthesis Inhibitors, RNA, Messenger, Receptor, Epidermal Growth Factor, Transforming Growth Factor alpha, Urinary Bladder Neoplasms",
author = "S{\o}rensen, {Boe Sandahl} and Niels T{\o}rring and Bor, {Mustafa Vakur} and Ebba Nex{\o}",
year = "2004",
month = "5",
language = "English",
volume = "260",
pages = "129--35",
journal = "Molecular and Cellular Biochemistry",
issn = "0300-8177",
publisher = "Springer",
number = "1-2",

}

The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. / Sørensen, Boe Sandahl; Tørring, Niels; Bor, Mustafa Vakur; Nexø, Ebba.

I: Molecular and Cellular Biochemistry, Bind 260, Nr. 1-2, 05.2004, s. 129-35.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced

AU - Sørensen, Boe Sandahl

AU - Tørring, Niels

AU - Bor, Mustafa Vakur

AU - Nexø, Ebba

PY - 2004/5

Y1 - 2004/5

N2 - Increased activity of the EGF system exerts a cell survival function in the presence of cytotoxic agents. The aim of our investigation was to identify the ligands and receptors from the EGF system, that are induced by the chemotherapeutic DNA damaging agent VP16 in bladder cancer cell lines. By use of real-time RT-PCR assays for all four receptors and six ligands from the EGF system we demonstrate that in HCV29 bladder cancer cells, amphiregulin, HB-EGF, and epiregulin mRNA levels are elevated (more than 100, 5, and 4 fold, respectively) by VP16. The remaining ligands (EGF, TGFalpha and betacellulin) are uninduced. The same was found for T24A bladder cancer cells, except that TGFalpha also was induced. The four receptors were reduced by VP16 in both cell lines. This demonstrates that the induction of the EGF system is mediated by an increased expression of a subset of the ligands, whereas the four receptors are reduced. For amphiregulin and HER1 we investigated with ELISA assays if the effects of VP16 also were observed at the protein level. We found that VP16 increase the amount of amphiregulin peptide both in the cell membrane and the culture medium. Similarly, the reduced EGF receptor mRNA expression correlated with reduced HER1 protein. Several investigations have shown that labile protein factors can be involved in the regulation of stress inducible growth factors and cytokines. We investigated if a labile protein regulates the expression of the subset of ligands that were induced with VP16. Blocking of protein neosynthesis with cycloheximide resulted in induced mRNA expression of exactly the same subset of ligands as observed with VP16 treatment of both HCV29 and T24A cells. This suggests that a labile protein factor regulates either the transcription or degradation of these mRNA's, and it can be speculated that VP16 also operate by inhibiting the activity of this factor. This is further stressed by the observation that combined treatment with cycloheximide and VP16 show no additive effect. In conclusion, we show that a subset of ligands from the EGF system is upregulated by VP16, whereas none of the four receptors are induced. This might represent a physiological response aimed at rescuing the cells.

AB - Increased activity of the EGF system exerts a cell survival function in the presence of cytotoxic agents. The aim of our investigation was to identify the ligands and receptors from the EGF system, that are induced by the chemotherapeutic DNA damaging agent VP16 in bladder cancer cell lines. By use of real-time RT-PCR assays for all four receptors and six ligands from the EGF system we demonstrate that in HCV29 bladder cancer cells, amphiregulin, HB-EGF, and epiregulin mRNA levels are elevated (more than 100, 5, and 4 fold, respectively) by VP16. The remaining ligands (EGF, TGFalpha and betacellulin) are uninduced. The same was found for T24A bladder cancer cells, except that TGFalpha also was induced. The four receptors were reduced by VP16 in both cell lines. This demonstrates that the induction of the EGF system is mediated by an increased expression of a subset of the ligands, whereas the four receptors are reduced. For amphiregulin and HER1 we investigated with ELISA assays if the effects of VP16 also were observed at the protein level. We found that VP16 increase the amount of amphiregulin peptide both in the cell membrane and the culture medium. Similarly, the reduced EGF receptor mRNA expression correlated with reduced HER1 protein. Several investigations have shown that labile protein factors can be involved in the regulation of stress inducible growth factors and cytokines. We investigated if a labile protein regulates the expression of the subset of ligands that were induced with VP16. Blocking of protein neosynthesis with cycloheximide resulted in induced mRNA expression of exactly the same subset of ligands as observed with VP16 treatment of both HCV29 and T24A cells. This suggests that a labile protein factor regulates either the transcription or degradation of these mRNA's, and it can be speculated that VP16 also operate by inhibiting the activity of this factor. This is further stressed by the observation that combined treatment with cycloheximide and VP16 show no additive effect. In conclusion, we show that a subset of ligands from the EGF system is upregulated by VP16, whereas none of the four receptors are induced. This might represent a physiological response aimed at rescuing the cells.

KW - Amphiregulin

KW - Antineoplastic Agents, Phytogenic

KW - Betacellulin

KW - Cell Line, Tumor

KW - Cell Membrane

KW - Cycloheximide

KW - Dose-Response Relationship, Drug

KW - EGF Family of Proteins

KW - Epidermal Growth Factor

KW - Epiregulin

KW - Etoposide

KW - Gene Expression Regulation, Neoplastic

KW - Glycoproteins

KW - Humans

KW - Intercellular Signaling Peptides and Proteins

KW - Ligands

KW - Protein Synthesis Inhibitors

KW - RNA, Messenger

KW - Receptor, Epidermal Growth Factor

KW - Transforming Growth Factor alpha

KW - Urinary Bladder Neoplasms

M3 - Journal article

VL - 260

SP - 129

EP - 135

JO - Molecular and Cellular Biochemistry

JF - Molecular and Cellular Biochemistry

SN - 0300-8177

IS - 1-2

ER -